Significant Ownership of Squadron Capital Management LLC
- Signature - Title
- /s/ Matthew Sesterhenn - Partner
- Location
- Westmont, IL
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Squadron Capital Management LLC.
Follow Filing Activity
Follow Squadron Capital Management LLC and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of Squadron Capital Management LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| RLMD | RELMADA THERAPEUTICS, INC. | Common Stock ($.001 par value) | 9.9% | $31,283,007 | +$17,330,352 | 7,395,510 | +124% | Squadron Master Fund LP | 31 Dec 2025 |
| NXTC | NextCure, Inc. | Common Stock, $0.001 par value per share | 9.9% | $3,521,940 | +$1,263,485 | 271,127 | +56% | Squadron Master Fund LP | 31 Dec 2025 |
| KTTA | Pasithea Therapeutics Corp. | Common Stock, par value $0.0001 per share | 9.9% | $2,050,179 | +$67,601 | 2,329,749 | +3.4% | Squadron Master Fund LP | 31 Dec 2025 |
| APRE | Aprea Therapeutics, Inc. | Common Stock | 9.9% | 1,271,081 | Squadron Master Fund LP | 30 Mar 2026 | |||
| SCYX | SCYNEXIS INC | Common Stock, par value $0.001 per share | 9.6% | $6,771,739 | 7,608,695 | Squadron Master Fund LP | 31 Mar 2026 | ||
| LPCN | Lipocine Inc. | Common Stock, par value $0.0001 per share | 9.5% | $5,549,100 | +$314,100 | 530,000 | +6% | Squadron Master Fund LP | 31 Dec 2025 |
| TRAW | Traws Pharma, Inc. | Common Stock, par value $.01 per share | 8.9% | $1,148,799 | +$197,289 | 713,540 | +21% | Squadron Master Fund LP | 31 Dec 2025 |
| SPRB | SPRUCE BIOSCIENCES, INC. | Common Stock, par value $0.0001 per share | 6.5% | $5,705,000 | 70,000 | 0% | Squadron Master Fund LP | 31 Dec 2025 | |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Common Stock,$0.001 par value per share | 5.1% | $9,376,095 | 3,676,900 | Squadron Master Fund LP | 24 Feb 2026 | ||
| PALI | PALISADE BIO, INC. | Common Stock, par value $0.01 per share | 3% | $8,640,000 | -$7,200,000 | 4,500,000 | -45% | Squadron Master Fund LP | 31 Dec 2025 |
Schedules 13D/G Reported by Squadron Capital Management LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.